SCHEMBL115677

SCHEMBL115677

Oc1ccc2cccnc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
CASP1 P29466 1/20 1.00
CASP7 P55210 1/20 1.00
HTT P42858 3/20 0.59
CYP1A2 P05177 2/20 0.59
CYP2C19 P33261 1/20 0.59
NR4A2 P43354 1/20 0.59
RECQL P46063 2/20 0.55
RAB9A P51151 2/20 0.55
TP53 P04637 2/20 0.55
CYP3A4 P08684 3/20 0.50
PDGFRB P09619 2/20 0.49
PDGFRA P16234 2/20 0.49
ESR2 Q92731 1/20 0.48
LMNA P02545 3/20 0.47
KDM4E B2RXH2 2/20 0.47
MAPT P10636 2/20 0.47
HIF1A Q16665 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29455006 1.00 ALDH1A1 (1.00) ALDH1A1MEN1KMT2ACASP1CASP7
SCHEMBL475177 0.98 ALDH1A1 (0.96) ALDH1A1MEN1KMT2ACASP1CASP7
SCHEMBL3680114 0.98 ALDH1A1 (0.96) ALDH1A1MEN1KMT2ACASP1CASP7
Bromide SCHEMBL30499298 0.98 ALDH1A1 (0.96) ALDH1A1MEN1KMT2ACASP1CASP7
SCHEMBL17580296 0.98 ALDH1A1 (0.96) ALDH1A1MEN1KMT2ACASP1CASP7
SCHEMBL8584630 0.98 ALDH1A1 (0.96) ALDH1A1MEN1KMT2ACASP1CASP7
Hydrochloric Acid SCHEMBL10445772 0.98 ALDH1A1 (0.96) ALDH1A1MEN1KMT2ACASP1CASP7
SCHEMBL4729030 0.98 ALDH1A1 (0.96) ALDH1A1MEN1KMT2ACASP1CASP7
SCHEMBL1567458 0.98 ALDH1A1 (0.96) ALDH1A1MEN1KMT2ACASP1CASP7
Methane SCHEMBL27562791 0.98 ALDH1A1 (0.96) ALDH1A1MEN1KMT2ACASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1438 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4539841-A2 HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2025-04-23 EP claimed
CN-114534694-B Hydroxyquinoline filler and preparation method and application thereof 万华化学集团股份有限公司 2024-08-16 CN claimed
EP-3386511-B2 METHODS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2024-03-20 EP claimed
CN-117509577-A Method for extracting phosphorus and reducing aluminum in wet phosphoric acid process by semi-water-dihydrate method 宜都兴发化工有限公司 2024-02-06 CN claimed
WO-2023244996-A2 HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. (US) 2023-12-21 WO claimed
CN-114534694-A Hydroxyquinoline filler and preparation method and application thereof 万华化学集团股份有限公司 2022-05-27 CN claimed
WO-2021086689-A1 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS AND USE THEREOF PRIME REACH TRADING LIMITED (WS) 2021-05-06 WO claimed
CN-108484495-B Synthetic method of 3-bromo-7-hydroxyquinoline 苏州康润医药有限公司 2021-05-04 CN claimed
US-10729630-B2 Shaping keratin fibres using an active agent comprising at least two functional groups selected from: —C(OH)- and —C(=O)OH THE PROCTER & GAMBLE COMPANY (US) 2020-08-04 US claimed
CN-105828786-B Shaping keratin fibres using AN AN active agent comprising a functional group selected from-C (═ O) -, -C (═ O) -H and-C (═ O) -O-) 宝洁公司 2020-07-07 CN claimed
WO-1998056899-A1 METHOD FOR ENHANCING THE ACTIVITY OF AN ENZYME, BLEACH COMPOSITION, DETERGENT COMPOSITION AND PROCESS FOR INHIBITING DYE TRANSFER UNILEVER N.V. (NL) 1998-12-17 WO claimed
WO-1998048799-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1998-11-05 WO claimed
US-5385990-A Blend of epoxy compound, amine hardener and hydroxy substituted aromatic compound LORD CORPORATION (US) 1995-01-31 US claimed
CN-1097452-A Colourless ultraviolet fluorescent identifier REN ENYANG (CN) 1995-01-18 CN claimed
CN-1087367-A Structural adhesive composition with high temperature resistance LORD CORP (US) 1994-06-01 CN claimed
EP-0596622-A2 Epoxy resin structural adhesive composition having high temperature resistance LORD CORPORATION (US) 1994-05-11 EP claimed
US-4807237-A Method and apparatus for operating a dye laser with a proton transfer reaction Max-Planck -Gesellschaft zur Forderung der Wissenschaften e.V. (DE) 1989-02-21 US claimed
EP-0258146-A1 Process for recovering the gallium contained in a sodium aluminate solution SOCIETE MINIERE ET METALLURGIQUE DE PENARROYA Société anonyme dite: (FR) 1988-03-02 EP claimed
US-4681814-A COMPLEX FORMING ORGANIC COMPOUND SURFACE LAYER LEHIGH UNIVERSITY (US) 1987-07-21 US claimed
US-4563253-A COMPLEXING ORGANIC COMPOUND WITH THIN OXIDE LAYER LEHIGH UNIVERSITY (US) 1986-01-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10729630-B2 Shaping keratin fibres using an active agent comprising at least two functional groups selected from: —C(OH)- and —C(=O)OH KRT18, CKAP4, JUP ALDH1A1 1821/4885MEN1 2788/4885KMT2A 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.